Search
5-methoxy-N,N-dimethyltryptamine
go.drugbank.com/drugs/DB14010IllicitInvestigationalIt is found in a wide variety of plant species, and a single psychoactive toad species, the Colorado River toad.
Enlonstobart
go.drugbank.com/drugs/DB21890Investigational[A274486] It targets the programmed cell death protein 1 (PD-1), is being developed by the CSPC Pharmaceutical Group for the treatment of advanced cervical cancer and other solid tumours.
Arsthinol
go.drugbank.com/drugs/DB08928ExperimentalIt has since been demonstrated that the agent possesses activity against amoebas and yaws.
Eperisone
go.drugbank.com/drugs/DB08992InvestigationalIt is not approved for use in the United States, but is available in other countries like India, South Korea, and Bangladesh.
Products: MYONAL TABLET 50MGCalcimycin
go.drugbank.com/drugs/DB19408InvestigationalIt binds to and transports calcium and other divalent cations across membranes, disrupts oxidative phosphorylation, and inhibits ATPase in rat liver mitochondria.
Aluminium monostearate
go.drugbank.com/drugs/DB01375ExperimentalAlso known as dihydroxyaluminium or dihydroxy(stearato)aluminium, it is used to form gels in the packaging of pharmaceuticals and in the preparation of colors for cosmetics.
1D-myo-inositol 1,4,5-trisphosphate
go.drugbank.com/drugs/DB03401ExperimentalInositol 1,4,5-trisphosphate is released into the cytoplasm where it releases calcium ions from internal stores within the cell's endoplasmic reticulum.
Zeteletinib
go.drugbank.com/drugs/DB21491InvestigationalZeteletinib is under investigation in clinical trial NCT03780517 (Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors).
Synonyms: Ret inhibitor ds-50101D09C3
go.drugbank.com/drugs/DB05121ExperimentalHuCAL(R) library of human antibodies. 1D09C3 binds to certain cell surface receptors, selectively killing activated, proliferating MHC class II-positive tumor cells, which include those in B-cell and T-cell
CCX915
go.drugbank.com/drugs/DB05159ExperimentalCCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders. The CCR2 receptor is thought to be of central importance ...